Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.
Mucosal Melanoma
DRUG: Toripalimab|DRUG: chemotherapy in combination with Endostar
Progression-Free Survival, PFS, PFS is defined as the time from the date of first treatment to the first occurrence of disease progression or death from any cause., Approximately 1 years
Objective Response Rate, ORR, ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions \>= 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)., Approximately 2 years|Overall Survival, OS, OS is defined as the time from the date of first treatment to death from any cause., Approximately 2 years|Incidence of AEs/SAEs, Percentage of Participants With Adverse Events/Severe Adverse Events, Approximately 2 years
This study is a multicenter, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.